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Stellingen behorende tot het proefschrift
development and use of biomarkers in clinical development  
of new therapies for chronic airway disease
1 rpl554, a dual pde3 and pde4 inhibitor, will be more successful for the 
treatment of copd then for allergic asthma because its anti-inflammatory  
effects seem confined to neutrophils (this thesis)
2 Serum Pulmonary Surfactant associated protein d is a potential biomarker  
for copd (this thesis)
3 The focus on allergic asthma has deprived many asthma patients of new 
treatments (this thesis). 
4 Selection of an allergic, corticosteroid responsive asthma population results  
in a homogeneous mrna fingerprint (this thesis)
5 Detailed understanding of the pathogenesis of asthma will result in innovative 
interventions (Stokes JR. Promising future therapies for asthma.  
Int Immunopharmacol. 2014 Nov;23(1):373-7)
6 The Inhaled allergen bronchoprovocation test has a fair positive predicted 
value and an excellent negative predictive value for the clinical efficacy of new 
antiasthma therapies (Diamant Z, Gauvreau GM, Cockcroft DW, Boulet LP, Sterk 
PJ, de Jongh FH, Dahlén B, O'Byrne PM. Inhaled allergen bronchoprovocation tests.  
J Allergy Clin Immunol. 2013 Nov;132(5):1045-1055)
7 Microorganism-induced suppression of allergic airway disease offers therapeutic 
options for the treatment of allergic asthma (Obieglo K, van Wijck Y, de Kleijn S, 
Smits HH, Taube C. Microorganism-induced suppression of allergic airway disease: 
novel therapies on the horizon? Expert Rev Respir Med. 2014 Dec;8(6):717-30)
8 A question-based approach to drug development is superior to the phase 1-4 
concept because it makes the development process transparent (Cohen AF. 
Developing drug prototypes: pharmacology replaces safety and tolerability?  
Nat Rev Drug Discov. 2010 Nov;9(11):856-65.). 
9 De helft van een schaatsmarathon is 34 rondjes (Masters competitie  
Jaap Edenbaan, Amsterdam)
10 Intelligentie is macht, karakter is meer (aangepast motto Nederlandse Defensie 
Academie)
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